Peter Sand to Solifenacin Succinate
This is a "connection" page, showing publications Peter Sand has written about Solifenacin Succinate.
Connection Strength
0.164
-
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jun; 20(6):667-75.
Score: 0.084
-
Elevating our therapeutic expectations in overactive bladder. J Am Acad Nurse Pract. 2004 Oct; 16(10 Suppl):8-11.
Score: 0.062
-
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006 Nov; 28(11):1935-46.
Score: 0.018